Pelican Therapeutics
LinkedIn

Heat Biologics, Inc. Heat Biologics, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Technology
    • Overview
    • ImPACT
    • ComPACT
    • Pelican’s PTX-35 Co-stimulatory Antibody
    • Scientific Publications
  • Product Pipeline
    • Overview
    • HS-110
    • HS-130
    • PTX-35
    • Expanded Access
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
    • Corporate Presentation
  • News & Media
    • News Releases
    • Events
  • Careers
  • Contact
  • Pelican Therapeutics

News Releases

News & Media

News & Media

  • News Releases
  • Events

Heat Biologics to Present at PIONEERS 2017 Presented by Joseph Gunnar & Co.

Apr 26, 2017

Heat Biologics Presents New Preclinical Data from OncoSec Collaboration at the American Association for Cancer Research (AACR) Annual Meeting

Apr 5, 2017

Heat Biologics Reports Fiscal Year 2016 Financial Results

Mar 31, 2017

Heat Biologics Closes Public Offering of 5,000,000 Shares of Common Stock

Mar 28, 2017

Heat Biologics Prices Offering of 5,000,000 Shares of Common Stock

Mar 23, 2017

Heat Biologics Announces Proposed Public Offering of Common Stock

Mar 22, 2017

Heat Biologics Reports Positive Interim Phase 2 Lung Cancer Results in Patients Treated with HS-110 in Combination with a Checkpoint Inhibitor

Mar 21, 2017

Heat Biologics, Inc. to Present at The MicroCap Conference on April 4th in New York City

Mar 20, 2017

Florida Department of Health Awards Three-Year Grant to Develop gp96-based Zika Vaccine

Mar 16, 2017

Heat Biologics Meets Efficacy Endpoint in its Phase 1b Lung Cancer Trial to Progress to Phase 2

Mar 13, 2017
    • 1...
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • ...21
    © 2019 Heat Biologics, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap LinkedIn